Junshi/IMPACT’s Senaparib Faces Crowded PARP Inhibitor Field
Executive Summary
The companies said their Phase III ovarian cancer study met its primary endpoint, but the market for PARP inhibitors has come under domination by Lynparza and Zejula.
You may also be interested in...
Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?
AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.
Clovis Close To Bankruptcy As Cancer Drug Outlook Worsens
Troubles are mounting for Clovis and its PARP inhibitor Rubraca, and now the company looks to be just months from bankruptcy.
New Front Opens in First-Line Ovarian Cancer Market: GSK’s Zejula Vs. AZ’s Lynparza
Two new PARP inhibitor studies – GSK’s PRIMA and AstraZeneca/Merck & Co.’s PAOLA-1 – are set to widen the ovarian cancer market after they reported highly positive first-line results in advanced patients at ESMO.